A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
about
Targeted destruction of photosensitive retinal ganglion cells with a saporin conjugate alters the effects of light on mouse circadian rhythms.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemiaImmunotherapy in autoimmune type 1 diabetesEngineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectorsSilencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphomaProspective data collection of off-label use of rituximab in Australian public hospitals.From a library of MAG antagonists to nanomolar CD22 ligands.Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastorisImproved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era.Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcomeIn vivo targeting of B-cell lymphoma with glycan ligands of CD22.Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions.Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry.Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas.Obesity and non-Hodgkin lymphoma survival in an ethnically diverse population: the Multiethnic Cohort study.Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to RituximabCoiled-coil based drug-free macromolecular therapeutics: in vivo efficacy.The development of potential antibody-based therapies for myelomaDrug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric NanomedicinesNutritional factors and non-Hodgkin lymphoma survival in an ethnically diverse population: the Multiethnic Cohort.Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.Rituximab in the treatment of pemphigus vulgaris.Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosisTransient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells.The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patientsCell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis.Emerging therapies for B-cell non-Hodgkin lymphoma.Sensitizing protective tumor microenvironments to antibody-mediated therapy.Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.Review of the safety and feasibility of rapid infusion of rituximab.Added value of molecular targeted agents in oncology.Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.B-cell targeted therapeutics in clinical development.Autoimmunity and inflammation in status epilepticus: from concepts to therapies.
P2860
Q21144236-CDF2483E-1DE2-4259-9A59-2F5EBAF3DAA9Q24594920-833E87D0-89C8-4E0D-AE14-2EA559917E3EQ27025619-DAA16A22-7444-4D79-948D-D556D8F72EFFQ27488806-A5882214-9FA7-4B06-9F54-1EA49119AA2AQ28486745-4A4818C9-54C9-4443-9A6A-3D2F4E3B92B4Q30640279-546E936C-BB12-4098-9275-B2B5112C8DB4Q31032076-5967245E-E8D4-44C5-BEF9-D98709AF1D8BQ33413834-6DBD2A35-5E28-4CC3-A85A-DC1CDF1DD786Q33492560-82E32EBF-DDD6-4CB3-89B3-8FA305535DFFQ33585882-5921BC92-C396-4350-9286-AAA180F10D55Q33718809-AE3A2203-F47B-472F-8C6D-8E7FC5AC7D5BQ33903709-C59B40C8-BA41-43F3-8A28-28CE7BAA2C72Q33931886-203C5E4C-F9AC-4207-ACDE-8A7DD3593509Q34026374-B622295F-9195-4A86-A03A-7441A0ACF524Q34112470-FDD3CD01-094D-4172-AB40-1048E023E709Q34223872-E8DF14DF-4101-4575-86D9-D89842481A08Q34470480-A9569BAB-7434-4DBE-A2C5-081F965FFB62Q34503404-4F131EC6-6A8C-4F49-A2B9-08149AB2EFFEQ34991655-AAC8F06A-464F-426E-880A-E60CF7887657Q34995766-08E2A5E6-9EC6-4341-9AFD-F25648C658A4Q35633346-AF8873A4-F537-4FB9-A409-CB9758035D69Q35678195-93B35F49-5DEA-425F-AA2B-474BEF0963DFQ35788245-50EFDC57-DB51-4A89-94D0-80C1C5DE62B1Q35861726-3A79B07D-7358-4088-9408-51BCA848658DQ36035583-42D8BAC8-D971-4464-95FA-79E24FDCFAA9Q36060239-9BF93B7C-A56F-4A67-9E41-91D5C57F5E68Q36434853-67CC4500-13A1-4D6A-A547-C16DE7FC5BE8Q36611125-5CCC0B25-0A56-468C-8482-D6678125F7CEQ36673736-D03D502C-543D-4852-9884-9584555C046AQ36760447-CF402CFE-BE31-4AC7-B34D-BDFC97ECD7FFQ36826060-55C02432-D593-4FEE-88AC-F7D0B2AA1228Q37537969-0B0EF51F-0263-4206-A0A6-F97232D9A29CQ37598947-6D6F683D-CE46-4A79-8348-6D556331ECFFQ37683676-AFF0E727-B7BA-4DB4-AF4B-0A20198FAD86Q37693873-017E88B6-E861-4E1C-B30B-AA06D81975B5Q37769107-9ABC7A3E-0FE6-4033-8A5C-99DACD5D2AC0Q37837267-70E64DE0-3593-4B73-8BCC-087E31C7AF82Q37883029-9E5EF32A-D43E-455A-8D00-9E096F412DCFQ38097162-B29FCEA7-0977-4B0D-B8B5-BF257C8385A7Q38247205-0E2C1145-0ADD-45EB-BA9B-41800B4DB7C6
P2860
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
@en
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
@nl
type
label
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
@en
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
@nl
prefLabel
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
@en
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
@nl
P1476
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
@en
P2093
Arturo Molina
P304
P356
10.1146/ANNUREV.MED.59.060906.220345
P577
2008-01-01T00:00:00Z